Long-term safety of daclizumab beta in patients with relapsing multiple sclerosis in EXTEND: Interim analysis for up to 6 years

Document Type

Presentation

Publication Date

2018

Keywords

oregon; providence neuroscience institute

Area of Special Interest

Neurosciences (Brain & Spine)

Specialty/Research Institute

Neurosciences

This document is currently not available here.

Share

COinS